


SL-73. DLK (MAP3K12) kinase inhibitors for CNS


The dual leucine zipper kinase (DLK or MAP3K12) is essential for neuronal development and has been explored as an attractive drug target for multiple neurodegenerative conditions [1].

A group from Genentech published several small molecule DLK inhibitors demonstrating desirable potency and good brain penetration following oral dosing [2].


80 analogs of the reported hits have been included in this library.




LAS 28291789



LAS 28294592



LAS 28296678



Initial Hit [2]

Signature Library 73

Formats	Supplementary Information
80 compounds per plate 0.1 mg; 1 mg; 2 mg dry film/powder 0.1 μ mol; 1 μ mol DMSO solutions	SL#73_DLK_inh.sdf

References:

- Expert Opin Ther Pat.*, 2016 May;26(5):607-16. doi: 10.1517/13543776.2016.1170810
- J. Med. Chem.*, 2012, 55 (3), pp 1242–1251 doi: 10.1021/jm201372q

Contact us:

USA: +1 336 721 1617
Japan: +81-80-3401-9097
Europe/Global:

mparisi@asinex.com
sota@asinex.com
lsadovenko@asinex.com